Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 7 min read

SLU-PP-332 vs CJC-1295 with DAC: what the research compares

A side-by-side look at what published work has measured for SLU-PP-332, a pan-ERR agonist chemical probe, and CJC-1295 with DAC, a GHRH analogue — including where the evidence is stronger and what remains unmeasured.

peptides-pro Editorial

SLU-PP-332 is a small synthetic agonist of the estrogen-related receptor (ERR) family, described in the literature as a pan-ERR agonist and exercise mimetic; it is a chemical probe rather than an approved drug, and the evidence block does not supply a sequence, formula or molecular weight for it [1][2]. CJC-1295 with DAC is a growth hormone-releasing hormone (GHRH) analogue, listed among the GHRH analogues encountered in clinical practice and in online self-administration protocols, alongside sermorelin, tesamorelin and CJC-1295 without DAC [3].

The two compounds sit in different receptor families: the SLU-PP-332 work centres on estrogen-related receptor signalling, while the CJC-1295 with DAC work centres on the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis [2][3].

Research Studies

SLU-PP-332 and ERR agonism in cell-based assays

SLU-PP-332 is described as a well-established exercise mimetic and a widely used chemical probe for ERR activation, but the structural features governing its potency, efficacy, selectivity and drug-like properties had not been systematically elucidated [2]. A structure-activity relationship (SAR) analysis of the SLU-PP-332 scaffold was reported, integrating chemical synthesis, cell-based functional assays, downstream gene-expression profiling and further work [2]. That study is the first comprehensive SAR analysis of the scaffold [2].

SLU-PP-332 and ERR signalling in skeletal muscle myoblasts

ERRs have been suggested as a therapeutic target to counteract muscle decline associated with aging or inactivity, on the basis that they regulate mitochondrial function and cellular respiration by up-regulating key factors in muscle responses to exercise [8]. One pilot study evaluated ERR targeting in myoblasts isolated from the skeletal muscle of inactive women, assessing metabolic and expression changes associated with ERR activation [8]. Twenty women undergoing hip arthroplasty for coxarthrosis were enrolled and divided into an active group (n = 10) and an inactive group (n = 10) based on self-reported physical activity [8].

SLU-PP-332 and in vitro metabolism

SLU-PP-332 and SLU-PP-915 were characterized using liquid chromatography–high resolution (tandem) mass spectrometry (LC-HRMS/MS), and in vitro metabolic transformation products of both compounds were prepared using human liver S9 fractions [1]. The rationale given for that work was that ERR agonists are being investigated as exercise mimetics because of their ability to trigger human physiological processes similar to those initiated by physical activity, which prompted consideration of these compounds as drugs potentially relevant to sports drug testing programmes [1].

SLU-PP-332 and doping-control detection

A separate analysis and identification of in vitro metabolites of SLU-PP-332, described as an ERRα/β/γ agonist, was carried out for doping-control purposes [9]. That work reports that exercise mimetics mimic physical activity and prevent development and progression of chronic metabolic diseases including obesity and Type 2 diabetes, and that the World Anti-Doping Agency prohibits the use of exercise mimetics and metabolic modulators in sport [9].

CJC-1295 with DAC and the GH-IGF-1 axis

CJC-1295 with DAC is grouped with the GHRH analogues — sermorelin, tesamorelin and CJC-1295 without DAC — as one of the agents most commonly encountered in clinical practice and in online self-administration protocols intended to modulate the GH-IGF-1 axis [3]. The same review frames these agents as performance-enhancing drugs marketed as "research compounds" [3].

CJC-1295 with DAC and the peptide therapeutics literature

Peptide therapeutics have been reviewed as an emerging frontier in gerontological medicine, targeting hallmarks of aging that include metabolic dysfunction, telomere attrition, tissue repair impairment and hormonal decline [5]. That review covered mechanisms, clinical applications, evidence base and safety profiles of therapeutic peptides with demonstrated or potential applications in healthy aging and age-related conditions, drawing on PubMed, Scopus and regulatory databases including the FDA and WADA [5].

CJC-1295 with DAC and sports-medicine peptide reviews

Reviews of peptide use in sports medicine describe peptides as short amino acid chains occupying a pharmacological niche between small-molecule drugs and large proteins, with use expanding rapidly on patient demand for accelerated injury recovery and performance enhancement [6][7]. Those reviews contrast peptide drugs that have undergone a rigorous approval process evaluating safety and efficacy with a parallel gray market of unapproved compounds operating largely outside regulatory oversight [6][7]. Injectable peptides have been promoted for musculoskeletal recovery, tissue repair and performance enhancement, with clinical adoption outpacing high-quality evidence and regulatory consensus [11].

SLU-PP-332 and CJC-1295 with DAC: what the published work measured

DimensionSLU-PP-332CJC-1295 with DAC
ClassSmall synthetic pan-ERR agonist; exercise mimetic chemical probe [1][2]GHRH analogue peptide [3]
Pathway / receptor familyEstrogen-related receptors (ERRα/β/γ) [2][9]GH-IGF-1 axis [3]
Identifiers given in evidenceNone supplied (no sequence, formula or molecular weight) [1][2]None supplied (no sequence, formula or molecular weight) [3]
Analytical characterizationLC-HRMS/MS; in vitro metabolites via human liver S9 fractions [1]Not reported in the evidence block
Cell-based functional dataReported, within a scaffold SAR analysis [2]Not reported in the evidence block
Human tissue modelMyoblasts from skeletal muscle of inactive women (pilot, n = 20 enrolled) [8]Not reported in the evidence block
Regulatory / antidoping contextProhibited class: exercise mimetics and metabolic modulators (WADA) [9]Marketed as a research compound; GH-IGF-1 axis modulation [3]
Approval statusChemical probe, not an approved drug [2]Unapproved; grouped with gray-market peptides [3][6]

Where the evidence is stronger for one compound

For SLU-PP-332, the evidence block contains primary experimental work: a comprehensive SAR analysis of the scaffold with cell-based functional assays and downstream gene-expression profiling [2], LC-HRMS/MS characterization with in vitro metabolite generation in human liver S9 fractions [1], a metabolite-identification study for doping control [9], and a pilot study in myoblasts isolated from skeletal muscle of inactive women [8]. For CJC-1295 with DAC, the evidence block contains review-level material: it is named within a review of performance-enhancing peptides modulating the GH-IGF-1 axis [3], within a gerontological review of therapeutic peptides [5], and within sports-medicine reviews of approved and unapproved peptide therapies [6][7][11]. No primary experimental study of CJC-1295 with DAC appears in the evidence block.

What is simply not known

  • No sequence, molecular formula or molecular weight is supplied for either compound in the evidence block [1][2][3].
  • No head-to-head study comparing SLU-PP-332 and CJC-1295 with DAC appears in the evidence block.
  • No human efficacy data for SLU-PP-332 appears in the evidence block; the human-derived material is a pilot study in isolated myoblasts, not an outcome study [8].
  • No primary experimental data for CJC-1295 with DAC appears in the evidence block; the material is review-level [3][5][6][7][11].
  • No dosing, pharmacokinetic or safety data for either compound appears in the evidence block.

Purity and sourcing in the research-peptide market

An evaluation of research-grade peptides marketed directly to consumers assessed purity, measured abundance and endotoxin burden using a large publicly available independent testing dataset, and compared cost against compounded and FDA-approved alternatives; the dataset comprised 6441 products [4]. That study describes a rapidly expanding, largely unregulated gray market selling preparations directly to consumers for self-administration, with purported benefits including accelerated musculoskeletal injury recovery, muscle hypertrophy, fat loss and athletic performance enhancement [4]. Peptide supplements are often perceived as low risk despite the absence of efficacy or safety data [10].

If you are reading this for personal health reasons

The materials described here are sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp